A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
The Leukemia & Lymphoma Society (LLS) is leading this ground-breaking approach to improve cancer treatment. This trial, which will be led and managed by LLS, will take place at many academic research institutions throughout the U.S.A. LLS's goal is to test a number of drugs or drug combination in development to speed up approval and increase effectiveness of treatments for patients diagnosed with AML.
Acute Leukemia, new diagnosis and relapsed/refractory
*Adults age 60 or older at the time of diagnosis
*Previously untreated AML with no prior treatment other than hydroxyurea. Prior therapy for myelodysplastic syndrome (MDS), Myeloproliferateive syndromes (MPD) or aplastic anemia is permitted but not with Hypomethylating agents
*If your AML came back after treatment or did not respond to prior therapy for AML.
60 - n/a
Healthy Volunteers Needed
Duration of Participation
Participation will be dependent on enrollment to the sub study treatment trial associated with this master (umbrella) protocol. the sub studies will include a 7 day screening period, treatment period and follow-up 28 days after the treatment period ends. All subjects who discontinue treatment for any reason other than progressive disease or withdrawal of consent will be contacted every 90 days for information on their medical history for up to 5 years after study enrollment.
Clinical Trials Information Line
Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc